ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming…
Read More
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW…
Read More
Former director of the National Institute of Neurological Disorders and Stroke will help guide the Foundation’s science funding partnerships and…
Read More